Gilead Sciences stock enters HIV Glasgow data week

Gilead Sciences is putting its HIV pipeline in focus as HIV Glasgow 2026 runs from Sunday, November 8, through Wednesday, November 11. In a November 2 release, the company said it would present results from more than 50 studies, including late-breaking data and two oral presentations, across HIV prevention, treatment and cure research.

The breadth of the program gives investors several development angles to follow. Gilead plans to discuss twice-yearly lenacapavir in the Phase 2 PURPOSE 5 study, real-world Biktarvy outcomes, Phase 3 ARTISTRY results for the once-daily BIC/LEN combination, and Phase 3 ISLEND data on an investigational once-weekly oral regimen of islatravir and lenacapavir. The company also plans to present Phase 1b data on GS-3242, an investigational integrase inhibitor being studied with lenacapavir as a potential twice-yearly injectable treatment.

Gilead said PURPOSE 5 is evaluating persistence and safety for twice-yearly lenacapavir compared with daily oral Truvada in people in the United Kingdom and France who had not previously used daily oral pre-exposure prophylaxis. The study is relevant to commercial adoption because persistence with a prevention regimen can influence its real-world effectiveness, although the company has not released the final results in the announcement.

Several development stages converge

The treatment program also extends beyond established products. The Phase 3 ISLEND trials are testing the investigational once-weekly oral combination in diverse patient populations, including people switching from existing treatment. Gilead said presentations will cover efficacy, safety, patient preferences and quality-of-life outcomes through Week 48.

In August 2026, the U.S. Food and Drug Administration approved Bixlenvo, a once-daily combination of bictegravir and lenacapavir, for adults with HIV who are virologically suppressed and switching from a stable regimen without known resistance to the components. The company describes ISL/LEN as investigational, while its release says GS-3242 received FDA fast-track designation in October. Neither designation establishes approval or commercial success.

The release also includes an HIV cure research update on amtabafusp alfa, a bispecific T-cell engager being studied in a Phase 1b trial. Gilead cautions that the investigational agent has not been approved and that its safety and efficacy have not been established. For shareholders, the presentations therefore offer pipeline visibility rather than a confirmed near-term revenue contribution.

Gilead Sciences stock traded at 150.25 euros on Lang & Schwarz at 13:50 CET on Monday, November 9, 0.06 percent above the Xetra close of Friday, November 6. The real-time quote of Gilead Sciences stock reflects an intraday indication, while the clinical presentations remain the more important fundamental catalyst.

Upcoming HIV data could help investors assess whether Gilead can extend its leadership in HIV prevention and treatment through longer-acting and less frequent dosing options. The timing also matters because the company is balancing established commercial products with several programs that still face clinical and regulatory risk.

The wider market backdrop is covered in current market reports.

Further developments can be followed through More news and analyses on Gilead Sciences stock.

Source: Gilead Sciences.